|Bid||39.87 x 3000|
|Ask||40.31 x 1400|
|Day's Range||40.08 - 40.32|
|52 Week Range||36.41 - 42.36|
|Beta (3Y Monthly)||0.52|
|PE Ratio (TTM)||40.50|
|Earnings Date||Feb 1, 2017 - Feb 6, 2017|
|Forward Dividend & Yield||2.39 (5.81%)|
|1y Target Est||44.33|
Vaccines are one of the biggest successes of modern medicine. They save up to 3 million people worldwide every year. From research and discovery to product development, it can cost up to a billion dollars to make one vaccine, and that process — can last up to 15 years. During the past few decades the number of companies producing vaccines has dwindled to just a handful. The four big drug companies that now dominate the market are Merck, Pfizer, Sanofi Pasteur and GlaxoSmithKline.
Key highlights of the week include Merck's (MRK) offer to buy private cancer biotech and AbbVie (ABBV) and Lilly's (LLY) updates from clinical studies.
The pharmaceutical giant also said it will be making changes to its incentive program for sales representatives.
Loosening the reins on bonuses will "uphold our ethical and values-led approach to (healthcare professional) engagement, in full compliance with laws and policies, whilst supporting delivery of strong performance," GSK said in a statement on its website. In 2012, the British group scrapped performance-based payments in the U.S. to avoid a repeat of aggressive sales practices.
The company said the vaccine will be introduced in phases in China, starting in 2020, to ensure reliable supply to all countries, where it has been launched. Shingrix, which has already been approved for use in the European Union, the United States, Canada, Japan and Australia, brought in 357 million pounds in the latest quarter. The approval comes after China included the vaccine in a list of 48 "clinically urgently needed new medicines" designated for faster review.
The company said the changes reflected the shift in GSK's portfolio towards innovative specialty care products, including oncology. GSK said it would make changes to its incentive program for pharmaceutical and vaccines sales representatives, to be applied initially in the United States, UK and Canada from July 2019. In specialty care, the capped variable pay element of a sales representative's salary will be evaluated on the basis of individual sales targets, it said.
GlaxoSmithKline is to reintroduce performance-based bonuses linked to the number of prescriptions written for its medicines, reversing a company ban on the practice following a bribery scandal in the US. The UK drugmaker said on Thursday that the return to incentives based on the number of prescriptions issued for its medicines in part reflected its growing portfolio of cancer drugs. GSK said that after a review of rival drugmakers’ policies on incentives, a return to performance-based bonuses would mean GSK was “more competitive when it comes to recruiting, motivating and retaining sales representatives and sales management with the right levels of expertise and experience”.
Learn about the forces driving the Chinese economy and helping the country earn money. China has the first or second largest GDP in the world but is not nearly as developed as others in the top 10.
The latest acquisition aligns with Thermo Fisher's (TMO) strategy of enhancing capabilities of its Pharma Services through the right balance of capital investment, and merger and acquisition.
The Australian subsidiaries of British drugmaker GlaxoSmithKline and Swiss drugmaker Novartis misled customers and broke the law by promoting identical liniments as though they could treat specific ills, an Australian court found on Friday. The court said the companies admitted marketing Voltaren Osteo Gel as a treatment for osteoarthritis-related pain when its ingredients were the same as a cheaper Voltaren product, Emulgel. Judge Robert Bromwich said in a written decision that it was part of a "deliberate and considered marketing strategy".
The biotechnology and pharmaceutical industry has something for everyone. Whether you are looking for a mature dividend aristocrat like GlaxoSmithKline (GSK) or a small-cap upstart like Sarepta (SRPT) that can double in value overnight, the sector will provide an option that suits your preferred risk-reward profile. Warning! GuruFocus has detected 5 Warning Sign with GSK.
Expands global footprint for complex API manufacturing WALTHAM, Mass. , May 16, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced today that ...
Formulations of select antivirals will be developed using Matinas’ LNC platform delivery technology, which enables the development of a wide range of difficult-to-deliver molecules. Promising formulations will be tested in in vivo preclinical studies to identify a lead LNC-antiviral formulation to take forward in development.
Shandong Buchang Pharmaceuticals Co., whose chairman Zhao Tao has been caught up in the U.S. college admissions scandal, said in a statement Monday that it had received questions from the stock exchange over why its sales expenses amounted to a higher-than-average 59% of the company’s 2018 revenue of 13.7 billion yuan ($1.99 billion). The company, which sells herbal medicines and bio-pharmaceuticals, said that the sales expenses were for general marketing and consulting, but did not explain why it was higher than the industry average.
Four giant companies now dominate global vaccine sales. With newer and more expensive vaccines becoming available, the market value of vaccines could rise to $100 billion by 2025.
The two pharmaceutical giants in December said they would combine their consumer health businesses in a joint venture that would be 68 percent-owned by GSK. The Australian Competition and Consumer Commission (ACCC) said products produced and sold by GSK and Pfizer in Australia would face strong competition from other players. For example, GSK's well-known pain management product - Panadol - would face strong competition from Reckitt Benckiser's Nurofen.
Australia's competition regulator said on Thursday it will not oppose GlaxoSmithKline's deal to buy Pfizer's consumer healthcare business. The two pharmaceutical giants said in December they would combine ...
Theravance Biopharma (TBPH) retains its earlier issued guidance for 2019 operating loss sans non-cash share-based compensation in the range of $210-$230 million.